What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?

Unfortunately, I think the only way to avoid additional chemotherapy would be in the context of a clinical trial, where non-KRAS G12C inhibitors are being studied. From the perspective of a standard of care, I would still recommend chemotherapy. We don't have granular data to suggest dual checkpoint...

Though not FDA approved, ramucirumab and pembrolizumab have shown OS advantage in the phase 2 LUNG-MAP study, and have been anecdotally seen to have good responses.

BMS/Mirati KRYSTAL-7 is enrolling across the US. Genentech should be open or opening soon in this space as well. Apologies if I left any pharmaceutical company out!